<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20110907152029+02'00'</creation_date><modification_date>D:20110907152032+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-285_h_a_dec_12.pdf</pdf_file></head><body><section><header>european commission brussels, 5.9.2011 c(2011)6369 final</header></section><section><header>commission implementing decision of 5.9.2011 
 amending the marketing authorisation granted by decision c(2004)3653 for “apidra - 
 insulin glulisine”, a medicinal product for human use</header><p>(text with eea relevance) (only the german text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission implementing decision of 5.9.2011 
 amending the marketing authorisation granted by decision c(2004)3653 for 
 “apidra - insulin glulisine”, a medicinal product for human use</header><p>(text with eea relevance) (only the german text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 17(2) thereof, 
 having regard to the notification submitted by sanofi-aventis deutschland gmbh, under 
 article 15(1) of regulation (ec) no 1234/2008, 
 whereas: 
 (1)</p><p>the european medicines agency has informed the marketing authorisation 
 holder and the commission of its favourable opinion on the minor variation of 
 type ib, notified between 8 december 2010 and 26 july 2011, and of the need to 
 amend the decision granting the marketing authorisation. 
 (2)</p><p>the marketing authorisation should be updated and decision c(2004)3653 of 27 
 september 2004 should therefore be amended accordingly. the community 
 register of medicinal products should also be updated.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>(3) for the sake of clarity and transparency, it is appropriate, following the 
 amendment of part or parts of the annexes, to provide for a consolidated version 
 thereof. the annexes to decision c(2004)3653 should therefore be replaced, 
 has adopted this decision: 
 decision c(2004)3653 is amended as follows: 
 1) the following notification for a minor variation is added to the marketing 
 authorisation: 
 application number 
 scope (eu numbers affected)</p><p>emea/h/c/557/ib/34 
 c.i.3.a) (eu/1/04/285/001-036)</p><p>
 2) annex i is replaced by the text set out in annex i to this decision;</p><p>3) annex iii b is replaced by the text set out in annex iii b to this decision. 
 article 2 this decision is addressed to sanofi-aventis deutschland gmbh, d-65926 frankfurt am main, deutschland. 
 done at brussels, on 5.9.2011. 5.9.2011.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>